Caitlin Handy, Robert Wesolowski, Michelle Gillespie, Michael Lause, Sagar Sardesai, Nicole Williams, Michael Grimm, Mahmoud Kassem, Bhuvaneswari Ramaswamy
{"title":"Alpelisib治疗转移性乳腺癌患者的肿瘤溶解综合征。","authors":"Caitlin Handy, Robert Wesolowski, Michelle Gillespie, Michael Lause, Sagar Sardesai, Nicole Williams, Michael Grimm, Mahmoud Kassem, Bhuvaneswari Ramaswamy","doi":"10.1177/11782234211037421","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat <i>PIK3CA</i>-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.</p><p><strong>Methods: </strong>In the following case, we present a patient with hormone receptor-positive, HER2-negative, <i>PIK3CA</i>-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.</p><p><strong>Results: </strong>Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.</p><p><strong>Conclusion: </strong>Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"15 ","pages":"11782234211037421"},"PeriodicalIF":1.8000,"publicationDate":"2021-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/75/10.1177_11782234211037421.PMC8408891.pdf","citationCount":"3","resultStr":"{\"title\":\"Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.\",\"authors\":\"Caitlin Handy, Robert Wesolowski, Michelle Gillespie, Michael Lause, Sagar Sardesai, Nicole Williams, Michael Grimm, Mahmoud Kassem, Bhuvaneswari Ramaswamy\",\"doi\":\"10.1177/11782234211037421\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat <i>PIK3CA</i>-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.</p><p><strong>Methods: </strong>In the following case, we present a patient with hormone receptor-positive, HER2-negative, <i>PIK3CA</i>-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.</p><p><strong>Results: </strong>Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.</p><p><strong>Conclusion: </strong>Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.</p>\",\"PeriodicalId\":9163,\"journal\":{\"name\":\"Breast Cancer : Basic and Clinical Research\",\"volume\":\"15 \",\"pages\":\"11782234211037421\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/75/10.1177_11782234211037421.PMC8408891.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer : Basic and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11782234211037421\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Basic and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782234211037421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.
Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat PIK3CA-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.
Methods: In the following case, we present a patient with hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.
Results: Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.
Conclusion: Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.
期刊介绍：
Breast Cancer: Basic and Clinical Research is an international, open access, peer-reviewed, journal which considers manuscripts on all areas of breast cancer research and treatment. We welcome original research, short notes, case studies and review articles related to breast cancer-related research. Specific areas of interest include, but are not limited to, breast cancer sub types, pathobiology, metastasis, genetics and epigenetics, mammary gland biology, breast cancer models, prevention, detection, therapy and clinical interventions, and epidemiology and population genetics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
